Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
heart surgery cardiac surgeons

Timing is everything: Delaying noncardiac surgery after a heart procedure reduces risks

When patients require subsequent noncardiac surgery after a major heart operation, waiting at least 100 days is one way to limit the risk of an adverse event. Read the full analysis in JACC: Advances.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

The biggest names in TAVR are sharing new data at ACC.25

The country’s two biggest TAVR vendors both plan on making a splash at ACC.25. Medtronic and Edwards Lifesciences spoke to Cardiovascular Business about their plans for the three-day event in Chicago.

Laxmi Mehta explaining statins are no longer contraindicated for pregnant women

Is statin therapy safe for pregnant women?

Laxmi Mehta, MD, explained that the use of statins when treating pregnant women is no longer forbidden. However, she added, cardiologists should always discuss it first with their patients.

Inspiris Resilia aortic valve from Edwards Lifesciences

First-in-class SAVR valve from Edwards Lifesciences linked to positive 5-year outcomes

Researchers focused on a relatively young patient population, hoping to learn as much as possible about the surgical valve's safety and effectiveness over an extended period of time. 

Alnylam Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for vutrisiran, a subcutaneous injection the company sells under the brand name Amvuttra, to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

FDA approves vutrisiran to treat ATTR-CM

The subcutaneous drug, sold under the brand name Amvuttra, joins an ATTR-CM market that already includes Pfizer’s tafamidis (Vyndaqel, Vyndamax) and BridgeBio’s acoramidis (Attruby).

progress step forward business announce

Abbott makes IVL move as FDA approves new clinical trial

Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.

Video of Steven Bolling, MD, professor of cardiac surgery, University of Michigan, explaining trends in tricuspid valve repair and replacement at CRT 2025.

Key trends in transcatheter tricuspid valve interventions

Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

heart patient

New drug shows early potential to treat aortic stenosis in some patients without TAVR, SAVR

The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.

Displaying 105 - 112 of 11027

Around the web

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.